Dose optimization of brodalumab in moderate-to-severe plaque psoriasis: A case report

Brodalumab, a monoclonal antibody that targets the interleukin-17 receptor, is a new treatment option for moderate-to-severe plaque psoriasis with a unique mechanism of action. The current recommended dosing regimen is a 210-mg subcutaneous injection at weeks 0, 1, and 2, and every 2 weeks thereafter. We present a case of a patient with recalcitrant moderate-to-severe plaque psoriasis who required a higher maintenance dose frequency of 210 mg of brodalumab subcutaneously every week to achieve disease clearance. To our knowledge, this is the first report of a patient receiving a maintenance dose of 210 mg of brodalumab weekly. In patients with refractory plaque psoriasis only partially responsive to the recommended maintenance dose, an increase in frequency to every week may be worth consideration. Further research is required to elucidate the effectiveness and long-term safety of this regimen.